Ipsen Acquires Memo Therapeutics for Up to €700 Million

Global pharmaceutical giant Ipsen has agreed to acquire Memo Therapeutics AG, a Swiss biotechnology firm specializing in antibody-based therapies, in a deal that could reach a substantial €700 million. The transaction, which includes an upfront payment of €200 million and significant milestone-based tranches, underscores the robust value creation within the European biotech sector and highlights Ipsen's strategic expansion into novel therapeutic areas.

The acquisition centers on Memo Therapeutics AG's lead candidate, 'potravitug,' a Phase II antibody targeting BK polyomavirus (BKPyV). This virus poses a serious threat to kidney transplant recipients, often leading to graft failure. The drug has already garnered attention from regulatory bodies, receiving Fast Track designation from the U.S. FDA in May 2023 and Orphan Drug status in the EU in December 2025, signaling its potential to address a critical unmet medical need. The deal structure allows for substantial upside for Memo Therapeutics AG's shareholders, contingent on the successful development and commercialization of this promising asset.

Kurma Partners, a key shareholder in Memo Therapeutics AG and a member of the Eurazeo Group, has been instrumental in guiding the company towards this significant exit. Kurma Partners initially invested in Memo Therapeutics AG in 2024 as part of a CHF 45 million Series C financing round. This acquisition validates Kurma Partners' investment thesis and its proven ability to nurture and advance innovative biotech ventures through to successful liquidity events, aligning with its strategy of backing companies with strong scientific foundations and significant market potential.

This acquisition by Ipsen follows a pattern of strategic bolt-on deals within the pharmaceutical industry, particularly in the immunology and rare disease spaces. Recent comparable transactions include Ipsen's own acquisition of ImCheck, uniQure's purchase of Corlieve Therapeutics, and AstraZeneca's acquisition of Amolyt Pharma. These moves reflect a broader industry trend of large pharmaceutical companies seeking to bolster their pipelines with cutting-edge assets from agile biotech firms, especially those with advanced clinical-stage candidates addressing rare or underserved conditions. The market for antibody-based therapeutics continues to expand, driven by advancements in drug discovery and a growing understanding of disease mechanisms.

As part of the transaction's conditions, assets and personnel not directly related to 'potravitug' will be spun off into a new entity, Memorises Bio, which will remain under the ownership of Memo Therapeutics AG's current shareholders. This strategic separation ensures that Ipsen can focus on maximizing the potential of the BKPyV program while allowing the remaining business to pursue its own strategic objectives. The deal is anticipated to close in the third quarter of 2026, subject to regulatory approvals and other customary closing conditions.

The successful culmination of this deal is a testament to the scientific rigor and dedicated efforts of the Memo Therapeutics AG team, led by CEO Erik van den Berg. His leadership has been pivotal in advancing the company's pipeline and positioning it for this significant acquisition. The transaction is expected to have a positive impact on Ipsen's financial outlook for the current year, as previously factored into their guidance.